Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Update

Mangoceuticals, Inc. (NASDAQ:MGRX) was the target of a significant decline in short interest in January. As of January 30th, there was short interest totaling 321,070 shares, a decline of 40.1% from the January 15th total of 536,149 shares. Based on an average daily volume of 399,153 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.3% of the shares of the stock are sold short. Approximately 2.3% of the shares of the stock are sold short. Based on an average daily volume of 399,153 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

MGRX has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Mangoceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Insider Buying and Selling at Mangoceuticals

In other news, Director Alex P. Hamilton sold 125,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $1.22, for a total value of $152,500.00. Following the completion of the sale, the director directly owned 3,334 shares of the company’s stock, valued at $4,067.48. This represents a 97.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 143,333 shares of company stock valued at $173,700 in the last three months. Corporate insiders own 16.00% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mangoceuticals stock. Jane Street Group LLC bought a new stake in Mangoceuticals, Inc. (NASDAQ:MGRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 47,503 shares of the company’s stock, valued at approximately $35,000. Jane Street Group LLC owned approximately 0.29% of Mangoceuticals as of its most recent filing with the Securities & Exchange Commission. 56.72% of the stock is currently owned by hedge funds and other institutional investors.

Mangoceuticals Price Performance

Shares of Mangoceuticals stock traded up $0.00 during trading on Friday, reaching $0.40. 82,723 shares of the stock traded hands, compared to its average volume of 416,444. Mangoceuticals has a 52-week low of $0.34 and a 52-week high of $6.15. The business has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $1.50. The company has a market capitalization of $6.45 million, a price-to-earnings ratio of -0.11 and a beta of 2.71.

Mangoceuticals (NASDAQ:MGRX) last posted its earnings results on Friday, November 14th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $0.08 million during the quarter. Mangoceuticals had a negative return on equity of 114.63% and a negative net margin of 4,253.43%.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.